Neurotech Nets $35 Million

Neurotech Pharmaceuticals Inc., a Lincoln, R.I.-based developer of therapeutics for chronic retinal diseases, has raised $35 million in Series B funding. Burrill & Co. led the deal, and was joined by Versant Ventures, SV Life Sciences, Omega Fund, Nexus Medical Partners and Pound Capital. Return backers included Apax Partners France, Merlin Biosciences, Atlas Venture, Mayflower, Avida Group and Alpha Associates. www.neurotechusa.com